Flagship Harbor Advisors LLC purchased a new position in Baxter International Inc (NYSE:BAX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,064 shares of the medical instruments supplier’s stock, valued at approximately $280,000.

Several other hedge funds and other institutional investors also recently modified their holdings of BAX. Family Capital Trust Co bought a new position in shares of Baxter International in the fourth quarter worth $103,000. Grove Bank & Trust increased its position in shares of Baxter International by 526.0% in the third quarter. Grove Bank & Trust now owns 2,285 shares of the medical instruments supplier’s stock worth $143,000 after purchasing an additional 1,920 shares during the period. Cerebellum GP LLC bought a new position in shares of Baxter International in the fourth quarter worth $173,000. Steward Partners Investment Advisory LLC bought a new position in shares of Baxter International in the third quarter worth $175,000. Finally, Hutner Capital Management Inc. bought a new position in shares of Baxter International in the third quarter worth $203,000. Institutional investors own 83.75% of the company’s stock.

In other news, SVP Giuseppe Accogli sold 28,641 shares of Baxter International stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Jeanne K. Mason sold 33,350 shares of Baxter International stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $65.25, for a total value of $2,176,087.50. Following the sale, the senior vice president now directly owns 124,609 shares in the company, valued at $8,130,737.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,061,991 shares of company stock worth $325,245,035. Company insiders own 0.05% of the company’s stock.

A number of research analysts recently commented on BAX shares. Zacks Investment Research cut Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. Morgan Stanley raised their price target on Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 26th. Bank of America upgraded Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Evercore ISI began coverage on Baxter International in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $71.00 target price on the stock. Finally, Barclays lifted their target price on Baxter International from $70.00 to $73.00 and gave the company an “overweight” rating in a research report on Thursday, October 26th. Seven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. Baxter International has an average rating of “Buy” and a consensus target price of $68.64.

Baxter International Inc (NYSE:BAX) opened at $71.05 on Friday. Baxter International Inc has a 12-month low of $45.53 and a 12-month high of $71.06. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22. The stock has a market capitalization of $38,214.52, a PE ratio of 38.20, a price-to-earnings-growth ratio of 2.13 and a beta of 0.69.

Baxter International (NYSE:BAX) last released its earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. The firm had revenue of $2.71 billion for the quarter, compared to analysts’ expectations of $2.66 billion. During the same quarter in the previous year, the business posted $0.56 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. equities research analysts forecast that Baxter International Inc will post 2.43 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, January 2nd. Shareholders of record on Friday, December 1st were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date of this dividend was Thursday, November 30th. Baxter International’s dividend payout ratio is presently 34.41%.

COPYRIGHT VIOLATION NOTICE: “Flagship Harbor Advisors LLC Takes $280,000 Position in Baxter International Inc (BAX)” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://theolympiareport.com/2018/01/26/flagship-harbor-advisors-llc-takes-280000-position-in-baxter-international-inc-bax.html.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.